

Session II Genetic Predisposition to WM

Session Chair: Dr. Landgren (USA)

9:15 AM	Dr. Kyle (USA)	IgM MGUS and Smoldering WM.
9:30 AM	Dr. McMaster (USA)	Familial Studies in WM.
9:45 AM	Dr. Ogmundsdottir (ICELAND)	Familial Studies of Plasma Cell Disorders.
10:00 AM	Dr. Landgren (USA)	Risk Factors for LPL.
10:15 AM	Dr. Morra (ITALY)	Associated Cancers in WM: Clues for Common Genetic Predisposition.
10:30 AM	Panel Discussion	All Session II Speakers.

10:45 AM-11:15 AM

**Morning Session Break.
"Ballroom Foyer"**

Session III Cell Origins and Genetic Basis of WM

Session Chair: Dr. Treon (USA)

Section I:

11:15 AM	Dr. Zehentner (USA)	Intraclonal heterogeneity in LPL.
11:30 AM	Dr. Varettoni (ITALY)	Pathogenesis of WM by Analysis of Immunoglobulin Heavy Chain Gene Rearrangement and Clustering of BCR.
11:45 AM	Dr. Leleu (FRANCE)	6q abnormalities and A20 dysregulation in WM.
12:00 PM	Dr. Fonseca (USA)	High resolution genomic analysis in WM.
12:15 PM	Panel Discussion	All Section I Speakers

Section II:

12:30 PM	Dr. Treon (USA)	MYD88 L265P in WM.
12:45 PM	Dr. Garcia Sanz (SPAIN)	MYD88 L265P as a specific marker for WM.
1:00 PM	Z. Hunter (USA)	Mutational Landscape of WM revealed through WGS.
1:15 PM	Dr. Munshi (USA)	Comparative WGS of MM and WM: Similarities and Differences.
1:30 PM	Panel Discussion	All Section II Speakers

1:45 PM-2:45 PM

**Sessions Break and Lunch.
"Rose Island Room"**

Session IV Molecular Pathogenesis in WM

Session Chair: Dr. Ghobrial (USA)

- | | | |
|---------|-------------------|---------------------------------|
| 2:45 PM | Dr. Zhou (USA) | Ets-family dysregulation in WM. |
| 3:00 PM | Dr. Roccaro (USA) | Epigenetic dysregulation in WM. |
| 3:15 PM | Dr. Novak (USA) | JAK-STAT pathway in WM |
| 3:30 PM | Panel Discussion | All Session IV Speakers. |

3:45 PM-4:15 PM

**Afternoon Session Break.
"Ballroom Foyer"**

Session V Microenvironment and Immune Interactions in WM

Session Chair: Dr. Dimopoulos (GREECE)

- | | | |
|---------|---------------------|---|
| 4:15 PM | Dr. Terpos (GREECE) | Role of MIP1a in WM. |
| 4:30 PM | Dr. Hodge (USA) | Role of IL-21 in WM. |
| 4:45 PM | Dr. Ghobrial (USA) | Micro-environmental interactions in WM. |
| 5:00 PM | Panel Discussion | All Session V Speakers. |
| 5:15 PM | Dr. Munshi (USA) | Day Summary and
Adjournment |



**Opening Ceremonies
RoseCliff Estate
6:30pm to 11:00pm
August 23, 2012**



**7th International Workshop on
Waldenström's Macroglobulinemia
August 23-26, 2012
Newport, Rhode Island USA**

Friday, August 24, 2012

Hyatt Regency Hotel

Workshop Program

7:00-8:00 AM

Breakfast

Registration

Rose Island Room

Ballroom Foyer (7:00am-5:30pm)

Session VI Survival in WM: Are We Making Progress? [Debate]

Session Chair: Dr. Kyle (USA)

8:00 AM Dr. Dimopoulos (GREECE)

Survival in WM: Are We Making Progress? [NO].

8:15 AM Dr. Kristinsson (SWEDEN)

Survival in WM: Are We Making Progress? [YES].

8:30 AM Dr. Morel (FRANCE)

Survival in WM: Is OS or WM Specific Survival the right marker?

8:45 AM Panel Discussion

All Session VI Speakers.

9:00 AM -9:30 AM

Dr. Cheson (USA)

Special Guest Lecturer:

"Challenges to the Development of Novel Agents"

Session VII Novel Therapeutic Approaches to WM-Preclinical


Session Chair: Dr. Mitsiades (USA)

9:30 AM	Dr. Tai (USA)	Targeting WM with BTK inhibitors.
9:45 AM	Dr. Yang (USA)	Targeting WM with MYD88 and IRAK inhibitors.
10:00 AM	Dr. Mitsiades (USA)	Novel E3 Ligase and Proteasome Inhibitors for WM therapy.
10:15 AM	Dr. Sette (ITALY)	Targeting the TLR/IL1-R Signaling Pathway.
10:30 AM	Dr. Carrasco (USA)	Transgenic Mouse Model for WM utilizing MYD88 L265P.
10:45 AM	Panel Discussion	All Session VII Speakers

Session VIII Treatment of WM-Primary

Session Chair: Dr. Leblond (FRANCE)

11:00 AM	Dr. Maloney (USA)	Monoclonal Antibody therapy of WM.
11:15 AM	Dr. Leblond (FRANCE)	Primary Therapy of WM with Nucleoside Analogue Based Therapy
11:30 AM	Dr. Rummel (GERMANY)	Primary Therapy of WM with Bendamustine Based Therapy
11:45 AM	Dr. Dimopoulos (GREECE)	Primary Therapy of WM with Proteasome Inhibitor Therapy.
12:00 PM	Panel Discussion	All Session VIII Speakers



**12:30 PM- 2:00 PM
Poster Presentation Luncheon
"Rose Island Room"**

An afternoon Luncheon will accompany the accepted twenty two Waldenstrom's Macroglobulinemia and Multiple Myeloma poster presentations and will be available for viewing and discussion by the authors.

Session IX Treatment of WM- Salvage
 Session Chair: Dr. Advani (USA)

2:00 PM	Dr. Tedeschi (ITALY)	FCR in Salvage Therapy of WM.
2:15 PM	Dr. Ghobrial (USA)	Treatment of WM with inhibitors of PI3K/MTOR pathway.
2:30 PM	Dr. Thomas (USA)	Clinical Trial of Pomalidomide in WM.
2:45 PM	Dr. Advani (USA)	Clinical Trial of PCI32765 BTK inhibitor in WM.
3:00 PM	Dr. Gertz (USA)	ASCT as salvage therapy in WM.
3:15 PM	Dr. Kyriakou (UK)	Allo SCT as salvage therapy in WM.
3:30 PM	Panel Discussion	All Session IX Speakers.

Session X WM & MM Oral & Poster Abstract Presentations

Section I Waldenstrom's macroglobulinemia:
 Session Chair: Dr. Morra (ITALY)

4:00 PM	Dr. Novak (USA)	GPR34 Functions as a Novel Regulator of Cell Growth and Gene Expression in LPL/WM.
4:15 PM	Dr. Wechalekar (UK)	Treatment and outcome of 267 patients with IgM-related AL amyloidosis
4:30 PM	Dr. Trojani (Italy)	Gene expression profiling identifies different molecular signatures of WM vs. IgM MGUS.

Section II Multiple Myeloma:
 Session Chair: Dr. Barlogie (USA)

4:45 PM	Dr. Palumbo (Italy)	A phase I/II study of PCP in myeloma patients relapsed/refractory to lenalidomide
5:00 PM	Dr. Plesner (Denmark)	Daratumumab-CD38 mAb- for the treatment of relapsed/refractory MM Patients:Preliminary efficacy and PK Data from a Multicenter Phase I/II study
5:15 PM	Dr. Lugui (China)	41/2 LIM Domains Protein 2 mediates Bortezomib-induced Osteogenic Differentiation of Mesenchymal Stem cells in MM through p53/p21 Pathway and beta-catenin activation
5:30 PM	Dr. Munshi (USA) Dr. Treon (USA)	Day Summary and Adjournment



**7th International Workshop on
Waldenström's Macroglobulinemia
August 23-26, 2012
Newport, Rhode Island USA**

Saturday, August 25, 2012

Hyatt Regency Hotel

7:00-8:00 AM

Breakfast
Registration

Rose Island Room
Ballroom Foyer (7:00am-5:30pm)

Session XI Treatment Debates in WM

Session Chair: Dr. Gertz (USA)

8:00 AM

Debate: Should nucleoside analogues be used in young patients with WM?

[YES]- Dr. Morra (ITALY)

[NO]- Dr. Leleu (FRANCE)

8:30 AM

Debate: Should Benda-R be considered for frontline therapy in WM?

[YES]- Dr. Rummel (GERMANY) [NO]- Dr. Gregory (USA)

9:00 AM

Debate: Should maintenance rituximab be used for rituximab responders in WM?

[YES]- Dr. Maloney (USA)

[NO]- Dr. Kimby (SWEDEN)

9:30 AM

Debate: Should ASCT be a frontline option for WM?

[YES]- Dr. Barlogie (USA)

[NO]- Dr. Femand (FRANCE)

10:00 AM- 10:30 AM

**Morning Session Break.
"Ballroom Foyer"**

Session XII**Special Topics in the Treatment of WM**

Session Chair: Dr. Stone (USA)

10:30 AM	Dr Stone (USA)	Role of Plasmapheresis in WM management.
10:45 AM	Dr Hochberg (USA)	Diagnosis and Management of Bing Neel Syndrome
11:00 AM	Dr Lunn (UK)	Diagnosis and Management of IgM Related Peripheral Neuropathy
11:15 AM	Dr Merlini (ITALY)	Advances in the Diagnosis and Management of systemic Amyloidosis
11:30 AM	Panel Discussion	All Session XII Speakers.

Session XIII**Response Assessment in WM**

Session Chair: Dr. Morel (FRANCE)

11:45 AM	Dr Owen (UK)	Challenges with current response criteria in WM.
12:00 PM	Dr Uljon (USA)	Challenges with Serum Protein Electrophoresis in assessing progression and clinical responses.
12:15 PM	C. Tripsas (USA)	Response Assessment using M-Component and Total Serum IgM in WM.
12:30 PM	Dr Garcia-Sanz (ITALY)	Stringent CR assessment in WM using flow cytometric assessment.
12:45 PM	Z. Hunter (USA)	MYD88 L265P as a response marker in WM.
1:00 PM	Panel Discussion	All Session XIII Speakers

1:15 PM-2:15 PM**Sessions Break and Lunch.
"Rose Island Room"**

Session XIV Advances in Multiple Myeloma

Session Chair: Dr. Anderson (USA)

2:15 PM	Dr. Munshi (USA)	Predictive Genomics and the Treatment of MM.
2:30 PM	Dr. Barlogie (USA)	Frontline Approaches to the Treatment of MM.
2:45 PM	Dr. Richardson (USA)	Treatment Approaches to Relapsed and Refractory MM.
3:00 PM	Dr. Palumbo (ITALY)	Maintenance Treatment Options in MM: Risk vs. Benefit.
3:15 PM	Dr. Anderson (USA)	Novel Treatment Approaches to MM.
3:30 PM	Dr. Landgren (USA)	Novel management of high-risk smoldering myeloma.
3:45 PM	Debate: ASCT is dispensable in MM patients in the Era of Novel Agents?	
	YES- Dr. Fermand (FRANCE)	NO- Dr. Barlogie (USA)
4:15 PM	Panel Discussion	All Session XIV Speakers.
4:45 PM	Dr. Anderson (USA) Dr. Munshi (USA)	Day Summary and Adjournment



***Closing Ceremonies
Marble House Estate
6:30pm to 11:00pm***



**7th International Workshop on
Waldenström's Macroglobulinemia
August 23-26, 2012
Newport, Rhode Island USA**

Sunday, August 26, 2012

Hyatt Regency Hotel

Consensus Panels & Workshop Review for Patients

7:00-8:00 AM

Breakfast

Registration

Rose Island Room

Ballroom Foyer (7:00-17:30)

Consensus Panels

8:00 AM Consensus Discussions on Treatment Options in WM

9:00 AM Consensus Discussions on Response Criteria in WM

10:00 AM- 10:30 AM

**Morning Session Break.
"Ballroom Foyer"**

10:30 AM – 12:30 PM Workshop Review for Patients

10:30 AM Dr. Kyle (USA)

10:45 AM Dr. Stone (USA)

11:00 AM Dr. Leblond (FRANCE)

11:15 AM Dr. Morra (ITALY)

11:30 AM Z. Hunter (USA)

11:45 AM Dr. Treon (USA)

12:00 PM Physician Panel

WM Diagnostic & Treatment Criteria.

Complications of WM.

Update on upfront Therapy in WM.

Update on Treatments of
Relapsed/Refractory in WM.

Revelation of MYD88 L265P as a
Novel Mutation in WM.

Update on Clinical Trials for WM.

Physician Q&A Lectures Discussion

12:30-1:30 PM

**Conclusion and Lunch.
"Rose Island Room"**